Brief: Q32 Bio Announces Completion Of Enrollment In SIGNAL-AD Phase 2 Trial Of Bempikibart For Atopic Dermatitis

Q32 Bio

09/07/2024 12:20

July 9 (Reuters) - Q32 Bio Inc  QTTB.O :
    * Q32 BIO ANNOUNCES COMPLETION OF ENROLLMENT IN THE
SIGNAL-AD
PHASE 2 CLINICAL TRIAL OF BEMPIKIBART FOR ATOPIC DERMATITIS
    * Q32 BIO INC - BEMPIKIBART TOPLINE RESULTS ON TRACK FOR
Q4'24

Source text for Eikon:  ID:nPn8P2nCYa 
Further company coverage:  QTTB.O 

 ((Reuters.Briefs@thomsonreuters.com;))